NASDAQ: DCTH - Delcath Systems, Inc.

六个月盈利: +51.2%
股息率: 0.00%
部门: Healthcare

促销时间表 Delcath Systems, Inc.

先进的时间表 简单图表
Financial Markets by TradingView

关于公司 Delcath Systems, Inc.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma.

更多详情
The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
添加到比较列表
添加到观察列表
添加到投资组合
添加价格通知

IPO date 2018-05-29
ISIN US24661P8077
Industry Health Care Equipment & Supplies
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.delcath.com
Цена ао 4.61
每日价格变化: -0.0835% (11.97)
每周价格变化: +8.63% (11.01)
每月价格变化: +6.6% (11.22)
3个月内价格变化: +30.93% (9.135)
六个月内的价格变化: +51.2% (7.91)
每年价格变化: +187.5% (4.16)
3年内价格变化: +44.44% (8.28)
5年内价格变化: +29 725.44% (0.0401)
10年价格变化: -0% (11.96)
年初以来价格变化: +9.72% (10.9)
所有参数

低估

姓名 意义 年级
P/S 31.52 1
P/BV 4.13 4
P/E 0 0
EV/EBITDA -1.67 0
全部的: 3.75

效率

姓名 意义 年级
ROA, % -123.48 0
ROE, % -302.2 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA -0.2898 10
全部的: 8

成长冲动

姓名 意义 年级
盈利能力 Revenue, % 29.06 4
盈利能力 Ebitda, % 154.76 10
盈利能力 EPS, % -99.44 0
全部的: 5.8
更多详情

ETF 分享, % 本年盈利能力, % 股息, %
iShares Micro-Cap ETF 0.0467 17.09 1.54048



导师 职称 支付 出生年份
Mr. Gerard J. Michel MBA, MS CEO & Director 727.97k 1963 (62 年)
Dr. Johnny John M.D. Senior Vice President of Clinical Operations & Medical Affairs 472.16k 1965 (60 年)
Ms. Sandra Pennell Senior VP of Finance and Principal Financial & Accounting Officer N/A 1980 (45 年)
Mr. David Hoffman General Counsel, Corporate Secretary & Chief Compliance Officer N/A
Dr. Martha S. Rook Ph.D. Chief Operating Officer N/A 1970 (55 年)
Dr. Vojislav Vukovic M.D., M.Sc., Ph.D. Chief Medical Officer 1967 (58 年)

地址: United States, New York. NY, 1633 Broadway - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.delcath.com